DOI

10.17077/etd.td3v9fr4

Document Type

Thesis

Date of Degree

Spring 2013

Degree Name

MS (Master of Science)

Degree In

Pathology

First Advisor

Janz, Siegfried

First Committee Member

Sunderland, John

Second Committee Member

Simons-Burnett, Andrean

Abstract

Emerging evidence indicates that 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are useful imaging modalities for evaluating tumor progression in transgenic mouse models of solid human cancers, but the potential of integrated FDG-PET/CT for assessing tumor development in genetically engineered mouse models of liquid human cancers - including neoplasms of immunoglobulin (Ig)-producing plasma cells - has not been established. Here we use a double-transgenic strain of laboratory mice, designated C.IL6Myc, that recapitulates key features of human plasma cell myeloma (a.k.a. multiple myeloma [MM]) to demonstrate that FDG-PET/CT affords a useful research tool for assessing plasma cell tumor (PCT) development in a serial, objective and, importantly, stage- and lesion-specific manner. Supported by serum biomarker analyses (Ig level, paraprotein) and histopathological findings in C.IL6Myc mice undergoing PCT development, the newly generated FDG-PET/CT data set demonstrates the potential of this imaging modality for preclinical basic and translational MM research. PET imaging of genetically engineered mice in which MM-like tumors arise predictably in an intact immunocompetent microenvironment may facilitate the design and testing of new approaches to the treatment and prevention of MM in humans.

Keywords

FDG-PET, IL-6, MLN2238, Myeloma, Proteasome inhibiton, Transgenic

Pages

vi, 94 pages

Bibliography

Includes bibliographical references (pages 86-94).

Copyright

Copyright 2013 Kaylia Duncan

Included in

Pathology Commons

Share

COinS